Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML.

Corbali M., Eskazan A. E.

Future oncology (London, England), vol.16, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Editorial Material
  • Volume: 16
  • Publication Date: 2020
  • Doi Number: 10.2217/fon-2020-0218
  • Journal Name: Future oncology (London, England)
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Keywords: acute myeloid leukemia, AML, idasanutlin, MDM2 inhibitor, relapsed or refractory, TP53, ACUTE MYELOID-LEUKEMIA, PLUS CYTARABINE
  • Istanbul University-Cerrahpasa Affiliated: Yes